Uniqure NV

NASDAQ QURE

Download Data

Uniqure NV Market Capitalization on June 03, 2024: USD 258.77 M

Uniqure NV Market Capitalization is USD 258.77 M on June 03, 2024, a -72.22% change year over year. Market capitalization is a financial metric that represents the total value of a publicly traded company. It is calculated by multiplying the current share price of a company by the total number of outstanding shares. Market capitalization is used to assess the size and relative value of a company in the stock market. It provides investors with an idea of the company's overall worth and is often used as a basis for comparing companies within the same industry or sector. A higher market capitalization generally indicates a larger, more established company.
  • Uniqure NV 52-week high Market Capitalization is USD 991.49 M on June 08, 2023, which is 283.16% above the current Market Capitalization.
  • Uniqure NV 52-week low Market Capitalization is USD 302.80 K on February 23, 2024, which is -99.88% below the current Market Capitalization.
  • Uniqure NV average Market Capitalization for the last 52 weeks is USD 354.23 M.
NASDAQ: QURE

Uniqure NV

CEO Mr. Matthew Craig Kapusta
IPO Date June 20, 2007
Location Netherlands
Headquarters Paasheuvelweg 25a, Amsterdam, Netherlands, 1105 BP
Employees 480
Sector Healthcare
Industry Biotechnology
Description

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Similar companies

ABOS

Acumen Pharmaceuticals Inc

USD 2.75

-6.46%

STRO

Sutro Biopharma

USD 4.10

-2.84%

DAWN

Day One Biopharmaceuticals Inc

USD 13.18

-0.68%

REPL

Replimune Group Inc

USD 5.44

3.23%

StockViz Staff

July 25, 2024

Any question? Send us an email